CONSTITUENT REPORT
trans-Anethole
trans-Anethole is the dominant sweet licorice-like phenylpropanoid in anise, star anise, and many fennel oils. In the AromaForge archive it functions primarily as a major identity and aroma driver rather than a niche trace constituent. Public literature is broad but uneven: identity and flavor-safety review support are strong, while many bioactivity claims come from preclinical models and should not be translated into medical language. The safest archive framing is that trans-anethole is a well-studied aromatic marker with preclinical anti-inflammatory and sensory-receptor data plus established food-flavoring safety review at ordinary intake levels.
Chemical identity and composition
NIST lists anethole with formula C10H12O and CAS 104-46-1, while the archive uses the trans isomer specifically because that is the dominant natural form in anise- and fennel-type oils. Search results and reviews also distinguish cis-anethole as a separate stereoisomer with different safety relevance.
Aroma and practical use
- Use the recorded sweet, licorice-like, anise-like, warm, spicy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2019 full-text study found that trans-anethole selectively activates TRPA1, then desensitizes it, and unlike allyl isothiocyanate did not provoke nocifensive behavior in mice in that model.
This is one of the clearest constituent-specific mechanism papers accessible in public results and is more defensible than broad wellness claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A full-text cancer-biology paper reported that anethole decreased pro-inflammatory cytokine production and inhibited NF-kappaB-regulated tumor-cell interactions in an in vitro and mouse metastasis model.
The study is mechanistically interesting but remains preclinical and should not be reframed as a human anticancer claim.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The FEMA GRAS safety review concluded that available data supported the use of trans-anethole as a flavoring substance under intended conditions of use.
This is the strongest directly relevant public safety synthesis for ordinary flavor use, although it is not a dermal-fragrance limit document.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A PubMed-indexed FEMA review supports trans-anethole as a flavoring substance under intended use conditions, which is stronger for ingestion-style flavor safety than for topical aromatherapy claims.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Alkenylbenzene reviews continue to discuss metabolite-related uncertainty for some exposure scenarios, so broad 'harmless' framing would overstate the evidence.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No standalone IFRA dermal cap for isolated trans-anethole was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
EugenolOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Eugenol report →LimoneneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · whole_oil
No source citation attached.
Read Limonene report →FenchoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
review · whole_oil
No source citation attached.
Read Fenchone report →How the effects were investigated
trpa1_selective_agonism_followed_by_desensitization
A full-text sensory-pharmacology paper reported that trans-anethole selectively activates TRPA1 and can subsequently desensitize the channel without the strong electrophilic reactivity typical of classic irritant agonists.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
inflammatory_mediator_downregulation_in_preclinical_models
Cell-based and animal studies consistently describe reduced inflammatory mediator signaling after trans-anethole exposure, but the evidence is still preclinical and model-dependent.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Many human-relevant claims around trans-anethole still depend on preclinical rather than clinical literature.
- Much of the public safety discussion focuses on flavor-use assessment or metabolite modeling rather than aromatherapy-style exposure.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.